AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29848400 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 32000
Study 28372549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (1.02 g over 2 doses)
Number of subjects: 296
Study 28372549 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (1.0 g over 10 doses)
Number of subjects: 296
Study 28372549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol and iron sucrose
Number of subjects: 296
Study 24656704 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat patch applied on the lower abdomen for 2 menstrual cycles
Number of subjects: 193
Study 24656704 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic medication (single dose)
Number of subjects: 193
Study 24656704 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 193
Study 21957983 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative communication
Number of subjects: 311
Study 21957983 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic communication
Number of subjects: 311
Study 21957983 — intervention group
Group type: COMPARATOR
Intervention: No message
Number of subjects: 311
Study 19489872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 208
Study 17961229 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic folate intake of 151-410 microg/d (2nd quartile)
Number of subjects: 108
Study 17961229 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma folate concentrations at 16 weeks postpartum
Number of subjects: 108
Study 17961229 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC folate concentrations at 16 weeks postpartum
Number of subjects: 108
Study 17961229 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall blood folate concentrations
Number of subjects: 108
Study 16240620 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-releasing hydroalginate dressing (Silvercel)
Number of subjects: 99
Study 16240620 — intervention group
Group type: COMPARATOR
Intervention: Pure calcium alginate dressing (Algosteril)
Number of subjects: 99
Study 12181401 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg daily
Number of subjects: 147
Study 12181401 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 600 mg daily
Number of subjects: 147
Study 9542794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 1
Study 9542794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 8031206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/d, increased to 40 mg/d and 80 mg/d based on response)
Number of subjects: 136
Study 8031206 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin (1.5 g/d, increased to 3 g/d and 4.5 g/d based on response)
Number of subjects: 136
Study 2919769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 30
Study 2919769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 30
Study 2919769 — intervention group
Group type: COMPARATOR
Intervention: No H2-antagonist (Control)
Number of subjects: 30
Study 31091372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg or 110 mg twice daily)
Number of subjects: 5390
Study 31091372 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 5390
Study 31091372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 5390
Study 31091372 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5390
Study 29175902 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oral aspirin daily for up to 24 weeks
Number of subjects: 251
Study 29175902 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for up to 24 weeks
Number of subjects: 251
Study 29175902 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oral aspirin daily
Number of subjects: 251
Study 29175902 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 251
Study 25499679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic unloader bracing with extension assist
Number of subjects: 52
Study 23492458 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-side stellate ganglion block (SGB) using 8 mL 0.75% ropivacaine for 4 times
Number of subjects: 30
Study 23492458 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 30
Study 23492458 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-side stellate ganglion block (SGB)
Number of subjects: 30
Study 21211691 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP + O(3) exposure
Number of subjects: 25
Study 21211691 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP + O(3) exposure with low-frequency to high-frequency ratio as covariate
Number of subjects: 25
Study 21211691 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP + O(3) exposure with high-frequency component as covariate
Number of subjects: 25
Study 17852073 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma beta-carotene
Number of subjects: 60
Study 17852073 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary F2-IsoP
Number of subjects: 60
Study 16855454 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil during open-label treatment
Number of subjects: 0
Study 16855454 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of Modafinil during double-blind treatment phase
Number of subjects: 0
Study 16855454 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study 16855454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12603352 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate‐based gel (HAbg) injected into the thoracic cavity (n = 27 patients)
Number of subjects: 52
Study 12603352 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injected into the thoracic cavity (Control group, n = 25 patients)
Number of subjects: 52
Study 10837282 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.1 g psyllium twice daily
Number of subjects: 0
Study 10837282 — intervention group
Group type: COMPARATOR
Intervention: Cellulose placebo
Number of subjects: 0
Study 9100159 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertensive group
Number of subjects: 20
Study 9100159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 1609906 — intervention group
Group type: EXPERIMENTAL
Intervention: ARTA public service announcement (appearing six times)
Number of subjects: 907
Study 1609906 — intervention group
Group type: COMPARATOR
Intervention: No AIDS public service announcements
Number of subjects: 907
Study 1609906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without ARTA PSA)
Number of subjects: 907
Study 4029247 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 0
Study 4029247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31005929 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome transfer (28 capsules of frozen microbial suspension)
Number of subjects: 80
Study 31005929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (28 capsules of saline)
Number of subjects: 80
Study 29174323 — intervention group
Group type: COMPARATOR
Intervention: 2+1 schedule (PCV13 at 2, 4, and 12 months)
Number of subjects: 213
Study 29174323 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+1 schedule (PCV13 at 3 and 12 months)
Number of subjects: 213
Study 29174323 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+1 schedule
Number of subjects: 213
Study 29174323 — intervention group
Group type: COMPARATOR
Intervention: 2+1 schedule
Number of subjects: 213
Study 29174323 — intervention group
Group type: EXPERIMENTAL
Intervention: Both schedules
Number of subjects: 213
Study 27422590 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg with telmisartan/amlodipine 40/5 mg
Number of subjects: 48
Study 27422590 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/amlodipine 40/5 mg with rosuvastatin 20 mg
Number of subjects: 48
Study 27422590 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 48
Study 27422590 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan/amlodipine 40/5 mg
Number of subjects: 48
Study 25370913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough wholegrain rye bread (WGR)
Number of subjects: 21
Study 25370913 — intervention group
Group type: EXPERIMENTAL
Intervention: White wheat bread enriched with bioprocessed rye bran (BRB+WW)
Number of subjects: 21
Study 25370913 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread (WW)
Number of subjects: 21
Study 22992309 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 282
Study 22992309 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 282
Study 22992309 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 282
Study 22992309 — intervention group
Group type: COMPARATOR
Intervention: Natural history group (no acupuncture treatment)
Number of subjects: 282
Study 22992309 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (Laser, Sham laser, Needle)
Number of subjects: 282
Study 20384520 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived cells (BMCs)
Number of subjects: 980
Study 20384520 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34(+) cell therapy
Number of subjects: 980
Study 18555814 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed start (initiation of contraception at the 1-week follow-up visit)
Number of subjects: 261
Study 18555814 — intervention group
Group type: COMPARATOR
Intervention: Sunday start (initiation of contraception at the first Sunday following the follow-up visit)
Number of subjects: 261
Study 16273791 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF blocker therapy
Number of subjects: 0
Study 16273791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin testing using PPD
Number of subjects: 0
Study 12484493 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona thinning (ZT) using a laser diode with 1.48 microm wavelength, 1-2 irradiations of 10 ms applied to four positions on the zona pellucida, thinning 60-90% of the ZP
Number of subjects: 100
Study 12484493 — intervention group
Group type: COMPARATOR
Intervention: No zona thinning (Control group)
Number of subjects: 100
Study 10320530 — intervention group
Group type: EXPERIMENTAL
Intervention: Banked human milk (BBM, n = 87)
Number of subjects: 244
Study 10320530 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula (PTF, n = 96)
Number of subjects: 244
Study 10320530 — intervention group
Group type: COMPARATOR
Intervention: Term formula (TF, n = 36)
Number of subjects: 244
Study 10320530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nutrient diet (BBM/TF)
Number of subjects: 244
Study 10320530 — intervention group
Group type: COMPARATOR
Intervention: Term children (n = 95)
Number of subjects: 244
Study 8738880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (0.5 IU, intravenous infusion within 2.5 min via a forearm catheter)
Number of subjects: 6
Study 8738880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2009998 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 1 mg/kg
Number of subjects: 21
Study 2009998 — intervention group
Group type: COMPARATOR
Intervention: Sulprostone 500 micrograms
Number of subjects: 21
Study 2009998 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX (1 mg/kg) systemic injection on days 3, 5, and 7 after local injection
Number of subjects: 21
Study 2009998 — intervention group
Group type: COMPARATOR
Intervention: Sulprostone (500 micrograms) systemic injection on the 1st 2 postlocal injection days
Number of subjects: 21
Study 2009998 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX and sulprostone
Number of subjects: 21
Study 7049099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic perfusion (cold crystalloid solution)
Number of subjects: 50
Study 7049099 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic potassium cardioplegia (cold crystalloid solution with 25 mEq/L potassium chloride)
Number of subjects: 50
Study 30707787 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 30
Study 30707787 — intervention group
Group type: COMPARATOR
Intervention: Control group (activity modification and night-only wrist splints)
Number of subjects: 30
Study 26759261 — intervention group
Group type: EXPERIMENTAL
Intervention: HP meal (31.9% energy from protein)
Number of subjects: 24
Study 26759261 — intervention group
Group type: COMPARATOR
Intervention: HMF meal (35.2% fat and 20.7% monounsaturated fat)
Number of subjects: 24
Study 27109624 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 (10 mg OD for 5 days)
Number of subjects: 56
Study 27109624 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX; 25 mg OD for 2 days, then 50 mg OD for 3 days)
Number of subjects: 56
Study 27109624 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 and Naltrexone
Number of subjects: 56
Study 27109624 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 56
Study 24896137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 10 mg/mL eye drops, instilled 4 times daily for 12 weeks (Study 2)
Number of subjects: 55
Study 24896137 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib 10 mg/mL eye drops, instilled 4 times daily for 2 weeks (Study 1)
Number of subjects: 55
Study 24896137 — intervention group
Group type: COMPARATOR
Intervention: Placebo, instilled 4 times daily for 2 weeks (Study 1)
Number of subjects: 55
Study 21897328 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic fibroblast growth factor (b‐FGF) group
Number of subjects: 63
Study 21897328 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 63
Study 21897328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 19212971 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for low panic-high worry and high panic-high worry sub-groups
Number of subjects: 170
Study 19212971 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for low panic-low worry subjects
Number of subjects: 170
Study 19212971 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for high worry subjects
Number of subjects: 170
Study 17202007 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.75%
Number of subjects: 203
Study 17202007 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 4%
Number of subjects: 203
Study 15041616 — intervention group
Group type: EXPERIMENTAL
Intervention: SUF group (7.5 microg of sufentanil)
Number of subjects: 300
Study 15041616 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE group (1.5 microg of sufentanil)
Number of subjects: 300
Study 15041616 — intervention group
Group type: EXPERIMENTAL
Intervention: EPD group (7.5 microg of sufentanil)
Number of subjects: 300
Study 15041616 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE groups (BSE and SUF)
Number of subjects: 300
Study 11174088 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturiser containing both urea and sodium chloride
Number of subjects: 22
Study 11174088 — intervention group
Group type: COMPARATOR
Intervention: Moisturiser containing urea alone
Number of subjects: 22
Study 9237315 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASD)
Number of subjects: 32
Study 9237315 — intervention group
Group type: COMPARATOR
Intervention: Open subacromial decompression (OSD)
Number of subjects: 32
Study 7584264 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory selective attention processes in working memory using a modified Sternberg‐type 'short‐term memory scanning' task.
Number of subjects: 0
Study 7584264 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory selective attention processes in working memory using a 'negative priming' task.
Number of subjects: 0
Study 3687783 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (50 micrograms/kg bolus then 0.5 microgram/kg/min)
Number of subjects: 14
Study 3687783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (2.5 to 15 micrograms/kg/min)
Number of subjects: 14
Study 31923099 — intervention group
Group type: EXPERIMENTAL
Intervention: Keto acid (KA) supplement (0.1 g/kg/day)
Number of subjects: 29
Study 31923099 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary protein intake of 0.9 g/kg/day)
Number of subjects: 29
Study 29449290 — intervention group
Group type: EXPERIMENTAL
Intervention: ReTrain intervention (including an introductory one-to-one session, ten twice-weekly group classes, a closing one-to-one session, and three drop-in sessions over 3 months)
Number of subjects: 45
Study 29449290 — intervention group
Group type: COMPARATOR
Intervention: Control group received an exercise after stroke advice booklet
Number of subjects: 45
Study 27134202 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic surgery
Number of subjects: 57
Study 27134202 — intervention group
Group type: COMPARATOR
Intervention: Medical weight management (MWM)
Number of subjects: 57
Study 24346625 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate acupuncture in the first 3 months
Number of subjects: 632
Study 24346625 — intervention group
Group type: COMPARATOR
Intervention: Delayed acupuncture in the subsequent 3 months
Number of subjects: 632
Study 24346625 — intervention group
Group type: EXPERIMENTAL
Intervention: Further acupuncture treatment during the follow-up period
Number of subjects: 632
Study 24346625 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture responder at 6 months
Number of subjects: 632
Study 24346625 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher school education
Number of subjects: 632
Study 24346625 — intervention group
Group type: EXPERIMENTAL
Intervention: Not wanting to use medications
Number of subjects: 632
Study 24346625 — intervention group
Group type: EXPERIMENTAL
Intervention: Using additional therapies
Number of subjects: 632
Study 22288578 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program conducted once a week for 90 minutes for 3 months
Number of subjects: 150
Study 20579837 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy-enhancing handout and CD
Number of subjects: 53
Study 20579837 — intervention group
Group type: COMPARATOR
Intervention: Expectancy-neutral informational handout and CD
Number of subjects: 53
Study 17286341 — intervention group
Group type: EXPERIMENTAL
Intervention: gender-specific feedback
Number of subjects: 185
Study 17286341 — intervention group
Group type: EXPERIMENTAL
Intervention: gender-neutral feedback
Number of subjects: 185
Study 17286341 — intervention group
Group type: COMPARATOR
Intervention: assessment-only control
Number of subjects: 185
Study 15644016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy for dependent smokers
Number of subjects: 210
Study 15644016 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 210
Study 12145026 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (1500 mg, intravenously every 3 months for 1 year)
Number of subjects: 20
Study 12145026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12145026 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 20
Study 10103334 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (3 mg/kg/d of elemental zinc as zinc sulfate)
Number of subjects: 87
Study 10103334 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 87
Study 10103334 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 87
Study 7757353 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular motor activity of the gastrointestinal tract
Number of subjects: 38
Study 2083042 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/2% Gantrez copolymer/0.243% sodium fluoride dentifrice
Number of subjects: 81
Study 2083042 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (same as experimental but without triclosan/copolymer)
Number of subjects: 81
Study 385025 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg piretanide
Number of subjects: 9
Study 385025 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg piretanide
Number of subjects: 9
Study 385025 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg bumetanide
Number of subjects: 9
Study 385025 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (6 mg piretanide, 9 mg piretanide, 1 mg bumetanide)
Number of subjects: 9
Study 385025 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg piretanide and 9 mg piretanide
Number of subjects: 9
Study 31014177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 75
Study 31014177 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 28044985 — intervention group
Group type: EXPERIMENTAL
Intervention: Drape on patient's arm (Group 2)
Number of subjects: 452
Study 28044985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic drape (Group 3)
Number of subjects: 452
Study 28044985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arm and pelvic drapes (Group 4)
Number of subjects: 452
Study 28044985 — intervention group
Group type: COMPARATOR
Intervention: No drapes (Group 1)
Number of subjects: 452
Study 26149841 — intervention group
Group type: EXPERIMENTAL
Intervention: pGM169/GL67A gene-liposome complex
Number of subjects: 140
Study 26149841 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 140
Study 23827100 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (PSL, 1.5 mg/kg for 2-4 weeks and subsequently stepwise reduction)
Number of subjects: 138
Study 23827100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (HDD, 40 mg/day, d1-4)
Number of subjects: 138
Study 23827100 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus HDD (rituximab 100 mg on days 7, 14, 21, 28 and HDD)
Number of subjects: 138
Study 23827100 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus HDD (R+HDD)
Number of subjects: 138